InsiderTrades.com logo
Neil Cashman net worth and biography
  • Phone
  • Email
  • Website

Neil Cashman Biography and Net Worth

Chief Scientific Officer and Co-founder of Promis Neurosciences

Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he held the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases (2005-2019) and served as the Director of the UBC ALS Centre until 2022. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000 and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

What is Neil Cashman's net worth?

The estimated net worth of Neil Cashman is at least $10.20 thousand as of February 10th, 2025. Dr. Cashman owns 664 shares of Promis Neurosciences stock worth more than $10,199 as of August 25th. This net worth evaluation does not reflect any other investments that Dr. Cashman may own. Learn More about Neil Cashman's net worth.

How do I contact Neil Cashman?

The corporate mailing address for Dr. Cashman and other Promis Neurosciences executives is 1920 Yonge Street Suite 200, Toronto A6, M4S 3E2. Promis Neurosciences can also be reached via phone at (416) 847-6898 and via email at [email protected]. Learn More on Neil Cashman's contact information.

Has Neil Cashman been buying or selling shares of Promis Neurosciences?

Neil Cashman has not been actively trading shares of Promis Neurosciences within the last three months. Most recently, on Monday, February 10th, Neil Cashman bought 600 shares of Promis Neurosciences stock. The stock was acquired at an average cost of $24.25 per share, with a total value of $14,550.00. Following the completion of the transaction, the insider now directly owns 664 shares of the company's stock, valued at $16,102. Learn More on Neil Cashman's trading history.

Who are Promis Neurosciences' active insiders?

Promis Neurosciences' insider roster includes Neil Cashman (Chief Scientific Officer and Co-founder), Johanne Kaplan (Chief Development Officer), and Eugene Williams (Chairman and Co-Founder). Learn More on Promis Neurosciences' active insiders.

Are insiders buying or selling shares of Promis Neurosciences?

In the last twelve months, Promis Neurosciences insiders bought shares 6 times. They purchased a total of 710,585 shares worth more than $8,655,727.23. The most recent insider tranaction occured on April, 22nd when Director Patrick D Kirwin bought 4,000 shares worth more than $45,320.00. Insiders at Promis Neurosciences own 1.5% of the company. Learn More about insider trades at Promis Neurosciences.

Information on this page was last updated on 4/22/2026.

Neil Cashman Insider Trading History at Promis Neurosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/10/2025Buy600$24.25$14,550.00664View SEC Filing Icon  
See Full Table

Neil Cashman Buying and Selling Activity at Promis Neurosciences

This chart shows Neil Cashman's buying and selling at Promis Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Promis Neurosciences Company Overview

Promis Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $15.36
Low: $14.50
High: $15.36

50 Day Range

MA: $13.31
Low: $10.16
High: $15.19

2 Week Range

Now: $15.36
Low: $6.27
High: $27.40

Volume

60,642 shs

Average Volume

106,621 shs

Market Capitalization

$137.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A